Dante Pieramici, MD
Retina Specialist · Santa Barbara, CANPI 1992804504
Payments from drug & device makers
Across 1,291 payments — averaging $11,692 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$9.6M
- Genentech, Inc.$4M
- Boehringer Ingelheim International GmbH$317K
- Apellis Pharmaceuticals, Inc.$307K
- Ocular Therapeutix, Inc.$253K
- Janssen Research & Development, LLC$232K
- plus $376K from 24 others
Across 31 payments — averaging $2621.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$70K
- Ocular Therapeutix, Inc.$10K
- Genentech, Inc.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $9,593,647 |
| Genentech, Inc. | 353 | $4,016,144 |
| Boehringer Ingelheim International GmbH | 336 | $316,507 |
| Apellis Pharmaceuticals, Inc. | 100 | $306,739 |
| Ocular Therapeutix, Inc. | 42 | $252,683 |
| Janssen Research & Development, LLC | 55 | $232,124 |
| AbbVie(2 entities) | 39 | $126,611 |
| Genentech USA, Inc. | 69 | $75,040 |
| Regeneron Healthcare Solutions, Inc. | 145 | $58,108 |
| Regeneron | 50 | $37,904 |
| F. Hoffmann-la Roche AG | 15 | $36,110 |
| Roche TCRC, Inc. | 2 | $29,355 |
| Eyepoint US, Inc. | 8 | $3,818 |
| Neurotech Pharmaceuticals, Inc. | 7 | $3,698 |
| Kyowa Kirin, Inc. | 1 | $1,725 |
| Samsung Bioepis Co., Ltd. | 1 | $950 |
| Alcon | 7 | $650 |
| Harrow Eye, LLC | 9 | $376 |
| Alimera Sciences, Inc. | 11 | $302 |
| Astellas Pharma US Inc | 8 | $261 |
| US Retina LLC | 2 | $255 |
| Biogen | 4 | $201 |
| NEW World Medical,inc. | 1 | $126 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $123 |
| Sun Pharmaceutical Industries Inc. | 1 | $97 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $83 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Bausch & Lomb Americas Inc. | 2 | $51 |
| Iridex Corporation | 1 | $49 |
| Oyster Point Pharma, Inc. | 2 | $40 |
How this compares
$15,093,845 in reported general payments places this provider in the 95th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Santa Barbara
- Dilsher DhootSanta Barbara$8.2M
- Nathan SteinleSanta Barbara$2.6M
- Alessandro CastellarinSanta Barbara$1.1M
- Nika BagheriSanta Barbara$528K
- Stephen CouvillionSanta Barbara$361K
- Robert AverySanta Barbara$190K
- Daniel LearnedSanta Barbara$146K
- Margaret ChangSacramento$13.2M
- Hani Salehi-HadHuntington Beach$12.2M
- Payam AminiPasadena$9.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.